19 recruiting, 11 active not recruiting, 5 not yet recruiting, 2 completed. 20 Phase 2, 11 Phase 1, 7 Phase 3, 1 Not applicable, 1 Phase 4.
Follow talquetamab: new trials by email Literature Review of talquetamab trials Research Report on talquetamab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BLOOD-dose: A Platform Trial Evaluating Dose Optimization in Hematological Diseases. teclistamab OR talquetamab OR elranatamab OR linvoseltamab, BTK inhibitors (ibrutinib and zanubrutinib) - Waldenstrom Macroglobulinaemia, Multiple Myeloma | Phase 4 | Not yet recruiting | Anne Louise Tølbøll Sørensen | 400 | 2027-03-01 | 2026-03-16 |
| Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple Myeloma Daratumumab and Recombinant Human Hyaluronidase, Lenalidomide, Bortezomib - Multiple Myeloma (MM) | Phase 2 / Phase 3 | Not yet recruiting | Alliance for Clinical Trials in Oncology | 920 | 2026-12-23 | 2026-10-22 |
| TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM) Talquetamab, Belantamab mafodotin, Pomalidomide - Relapse Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Not yet recruiting | Montefiore Medical Center | 50 | 2026-09-01 | 2026-07-22 |
| A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable Disease Teclistamab, Talquetamab, Daratumumab (Subcutaneously) - Multiple Myeloma (MM) | Phase 3 | Not yet recruiting | Polish Myeloma Consortium | 248 | 2026-09-01 | 2026-07-31 |
| Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography - Cytokine Release Syndrome, Recurrent Multiple Myeloma | Phase 2 | Recruiting | Naresh Bumma | 35 | 2026-07-17 | 2026-10-06 |
| Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level Daratumumab, Lenalidomide, Dexamethasone - Multiple Myeloma (MM), Plasma Cell Leukemia (PCL) | Phase 3 | Recruiting | University of Leeds | 1226 | 2026-07-01 | 2026-07-15 |
| Talquetamab in Patients With Refractory Generalized Myasthenia Gravis Talquetamab - Myasthenia Gravis (MG) | Not applicable | Not yet recruiting | First Affiliated Hospital of Chongqing Medical University | 2 | 2026-03-20 | 2026-04-08 |
| Mezigdomide and Talquetamab in Relapsed and Refractory Multiple Myeloma Talquetamab, Mezigdomide, Dexamethasone - Relapsed Refractory Multiple Myeloma (RRMM) | Phase 1 | Recruiting | Massachusetts General Hospital | 25 | 2025-12-19 | 2026-04-13 |
| Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab. Teclistamab, Talquetamab, Daratumumab - Multiple Myeloma (MM) | Phase 2 | Recruiting | European Myeloma Network B.V. | 150 | 2025-12-12 | 2026-04-15 |
| Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma Talquetamab, Ciltacabtagene Autoleucel - Relapse Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Recruiting | Medical College of Wisconsin | 31 | 2025-12-02 | 2026-01-05 |
| Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse Talquetamab, Daratumumab - Multiple Myeloma in Relapse | Phase 2 | Recruiting | Larysa Sanchez | 23 | 2025-11-18 | 2026-09-14 |
| External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary Disease Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Extramedullary Disease in Multiple Myeloma, Multiple Myeloma | Phase 1 / Phase 2 | Suspended | City of Hope Medical Center | 20 | 2025-08-29 | 2026-10-07 |
| Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE) Talquetamab, Teclistamab - Multiple Myeloma | Phase 2 | Recruiting | Noffar Bar | 50 | 2025-08-21 | 2026-05-13 |
| Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma Talquetamab, Iberdomide, Dexamethasone - Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Recruiting | Alfred Chung, MD | 32 | 2025-07-28 | 2026-03-13 |
| Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma Talquetamab, Talquetamab and Lenalidomide - Multiple Myeloma, Post Stem Cell Transplant | Phase 2 | Recruiting | Stanford University | 20 | 2025-06-05 | 2026-07-17 |
| The Norwegian Immunotherapy in Multiple Myeloma Study Teclistamab, Elranatamab, Ciltacabtagene Autoleucel - Myeloma Multiple, Plasma Cell Leukemia | Recruiting | St. Olavs Hospital | 400 | 2025-01-15 | 2026-07-20 | |
| A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma Cilta-cel, Talquetamab - Multiple Myeloma | Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 11 | 2024-09-16 | 2026-09-25 |
| A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events Talquetamab, Prophylaxis A, Prophylaxis B - Multiple Myeloma | Phase 2 | Recruiting | Janssen Research & Development, LLC | 210 | 2024-08-26 | 2026-09-25 |
| A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma Cilta-cel, Talquetamab, Daratumumab - Multiple Myeloma | Phase 2 | Active not recruiting | Janssen Research & Development, LLC | 43 | 2024-08-20 | 2026-09-25 |
| Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma Teclistamab, Talquetamab, Lenalidomide - Multiple Myeloma | Phase 2 | Active not recruiting | Nantes University Hospital | 103 | 2024-06-26 | 2026-03-17 |
Showing 20 of 41. Sign in to see all of them.
Multiple Myeloma (36) · Recurrence (4) · Neoplasm, Residual (3) · Cytokine Release Syndrome (2) · Hematologic Neoplasms (2) · Leukemia, Plasma Cell (2) · Frailty (1) · Immunoglobulin Light-chain Amyloidosis (1) · Infections (1) · Myasthenia Gravis (1) · Neoplasms, Plasma Cell (1) · Waldenstrom Macroglobulinemia (1)
Janssen Research & Development, LLC (15) · Alfred Chung, MD (1) · Alliance for Clinical Trials in Oncology (1) · Anne Louise Tølbøll Sørensen (1) · Carl Ola Landgren, MD, PhD (1) · Celgene (1) · City of Hope Medical Center (1) · European Myeloma Network B.V. (1) · First Affiliated Hospital of Chongqing Medical University (1) · Janssen Pharmaceutical K.K. (1) · Janssen-Cilag Ltd. (1) · Larysa Sanchez (1) · Massachusetts General Hospital (1) · Medical College of Wisconsin (1) · Memorial Sloan Kettering Cancer Center (1)
United States (25) · Spain (14) · Germany (10) · France (9) · Netherlands (9) · United Kingdom (8) · Australia (6) · Belgium (6) · Israel (6) · Italy (6) · Japan (6) · South Korea (6) · Brazil (5) · Denmark (5) · Norway (5)
Alessandra Larocca (1) · Alfred Chung, MD (1) · Andrew J. Yee, MD (1) · Carl O Landgren, MD, PhD (1) · Charlotte Pawlyn (1) · David R Levitz, MD (1) · Diana Loigom, MD (1) · Fredrik Schjesvold (1) · Gordon Cook (1) · Hira Shaikh, MBBS (1)
PMID 39155155, PMID 40090350, PMID 40631904, PMID 40864183, PMID 41313549, PMID 42299486, PMID 42561120, PMID 42669079, PMID 42803498, PMID 32040549, PMID 32956453, PMID 36507686, PMID 37173224, PMID 38402374, PMID 39778168, PMID 40983036, PMID 41036677, PMID 41358582, PMID 41405810, PMID 42294841, PMID 42350642, PMID 42685673
2023 (12), 2017 (2), 2019 (2), 2025 (1), P30CA033572 (1)